Skip to main content

Table 4 Postoperative outcomes

From: Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study

 

Control group, mean ± SD (n = 15)

Prehabilitation group, mean ± SD (n = 14)

p-value

Hospital stay (days)

7.8 ± 6.8

7.4 ± 5.0

0.700

ICU stay (days)

1.2 ± 0.6

1.2 ± 0.9

0.959

Time to start CT of surgery day (days)

39.9 ± 14.3

37.4 ± 9.2

0.602

Pain VAS day 1

1.6 ± 1.7

1.7 ± 1.7

0.856

Pain VAS day 2

1.2 ± 1.0

1.4 ± 1.4

0.736

Diet restart (days)

1.7 ± 0.8

1.3 ± 0.6

0.169

Deambulation restart (days)

3.1 ± 1.2

2.9 ± 1.4

0.678

Postoperative complications, n (%)

 Non reported

6 (40.0)

4 (28.6)

0.518

 Reported

9 (60.0)

10 (71.4)

Postoperative complications

 Paralytic ileus

2 (13.3)

1 (7.1)

0.584

 Surgical site infection (superficial and deep)

6 (40.0)

5 (35.7)

0.812

 Surgical site infection (organ and space)

2 (13.3)

0 (0)

0.157

 Anastomosis breakdown

2 (13.3)

0 (0)

0.157

 Cardiovascular

1 (6.7)

0 (0)

0.326

 Respiratory

3 (20.0)

1 (7.1)

0.316

 Neurological

0 (0)

2 (14.3)

0.129

 Urinary tract infection

4 (26.7)

1 (7.1)

0.164

 Multiorgan failure

1 (6.7)

0 (0)

0.326

Surgical reintervention

1 (6.7)

1 (7.1)

0.960

Clavien-Dindo complications

 I

4 (26.7)

4 (28.6)

0.486

 II

10 (66.7)

8 (57.1)

 III

0 (0)

1 (7.1)

 IV

0 (0)

1 (7.1)

 V

1 (6.7)

0 (0)

Readmissions

2 (13.3)

3 (21.4)

0.564

  1. CT chemotherapy, ICU intensive care unit, SD standard deviation, VAS visual analog scale